Superior Vena Cava Obstruction

Topic Overview

Summary

Superior vena cava obstruction (SVCO) represents compression, invasion, or thrombosis of the superior vena cava (SVC), impeding venous return from the head, neck, upper extremities, and upper thorax to the right atrium. [1] The condition is most commonly caused by intrathoracic malignancy, with lung cancer accounting for 50-70% of cases, followed by lymphoma (10-15%). [2,3] Classic clinical presentation includes facial and neck swelling (particularly worse on lying flat or bending forward), dilated non-pulsatile neck veins, upper limb oedema, and prominent chest wall collateral veins. [4] While SVCO is rarely immediately life-threatening, stridor from laryngeal oedema or symptoms of cerebral oedema (headache, confusion, visual disturbance, papilloedema) constitute true oncological emergencies requiring urgent intervention. [5]

Diagnosis is established through contrast-enhanced CT chest (CT venography), which delineates the site and extent of obstruction, identifies the underlying cause, and maps collateral circulation. [6] Management priorities include: (1) identifying and treating life-threatening features, (2) obtaining tissue diagnosis before initiating definitive treatment (except in emergencies), and (3) implementing appropriate oncological therapy. [7] Endovascular SVC stenting provides rapid symptomatic relief (within hours to days) in over 90% of patients and has become first-line palliative intervention. [8,9] Definitive treatment depends on the underlying malignancy: chemotherapy for chemo-sensitive tumours (small cell lung cancer, lymphoma), radiotherapy for palliation in non-small cell lung cancer (NSCLC), and anticoagulation for thrombotic SVCO. [10,11]

Dexamethasone (8-16 mg daily) is widely used to reduce peritumoral and laryngeal oedema, though evidence for efficacy is limited. [12] Prognosis correlates strongly with the underlying aetiology, with small cell lung cancer and lymphoma showing better response rates and survival compared to NSCLC. [13] Recognition of SVCO as a presenting feature of malignancy, systematic assessment for life-threatening complications, and coordinated multidisciplinary management involving oncology, interventional radiology, and respiratory medicine are essential clinical skills for MRCP candidates and oncology trainees.

Key Facts

• Most common cause: Malignancy in 85-90% of cases (lung cancer 50-70%, lymphoma 10-15%, metastatic disease 5-10%). [2,3]
• Benign causes: Increasing in frequency due to intravascular devices (central venous catheters, pacemakers, defibrillators) causing thrombosis; fibrosing mediastinitis; retrosternal goitre. [14,15]
• Classic triad: Facial/neck swelling + dilated neck veins + upper limb oedema
• Pemberton sign: Facial plethora, cyanosis, and respiratory distress developing within 1 minute of raising both arms above the head
• Life-threatening features: Stridor (laryngeal oedema), cerebral oedema (confusion, papilloedema, seizures), airway compromise
• Gold standard investigation: CT chest with IV contrast (CT venography) - sensitivity > 95% [6]
• First-line intervention: Endovascular SVC stenting - technical success > 90%, clinical improvement in 85-95% within 72 hours [8,9]
• Tissue diagnosis essential: Obtain histology before starting chemotherapy/radiotherapy unless life-threatening features present
• Chemotherapy-sensitive tumours: Small cell lung cancer (SCLC) and lymphoma respond rapidly to chemotherapy; stenting may not be required [10]
• Prognosis: Median survival 6-9 months for lung cancer-related SVCO, better for lymphoma (24-36 months with treatment) [13]

Clinical Pearls

SVCO is usually NOT an immediate emergency — Most patients are stable enough to undergo systematic investigation and tissue diagnosis before treatment. Avoid the historical reflex to give radiotherapy without histology. [7]

However, stridor or cerebral oedema = true emergency — These indicate critical airway or CNS compromise and require immediate intervention with dexamethasone, consideration of emergency stenting, and potential airway protection. [5]

SVC stenting provides rapid relief — Symptom improvement typically occurs within hours to days, making it ideal for palliative symptom control regardless of underlying cause. [8]

Chemotherapy alone may be sufficient — In chemo-sensitive tumours (SCLC, lymphoma), chemotherapy often provides rapid tumour shrinkage and SVCO resolution without need for stenting. [10]

Pemberton sign is specific but not sensitive — Positive in 50-60% of SVCO cases; absence does not exclude diagnosis, but presence strongly supports it. [16]

Collateral circulation determines symptom severity — Gradual onset allows collateral development (azygos, internal mammary, lateral thoracic veins), resulting in milder symptoms; rapid onset causes severe symptoms. [4]

Central line-associated SVCO is increasing — Iatrogenic thrombotic SVCO from long-term central venous catheters, PICC lines, pacemakers, and defibrillator leads now represents 20-30% of cases in some series. [14,15]

Why This Matters Clinically

SVCO is an important clinical syndrome for several reasons:

1. First presentation of malignancy: In 40-60% of lung cancer cases, SVCO represents the initial manifestation of disease, making it a critical diagnostic opportunity. [2]

2. Quality of life impact: Facial swelling, dyspnoea, and functional impairment significantly affect patient wellbeing; rapid symptomatic relief through stenting dramatically improves quality of life in advanced malignancy. [17]

3. Multidisciplinary challenge: Optimal management requires coordination between emergency medicine, respiratory medicine, oncology, radiology, and interventional radiology.

4. Prognostic implications: Recognition of SVCO allows staging, prognostication, and appropriate treatment planning for the underlying malignancy.

5. Iatrogenic prevention: Awareness of catheter-related SVCO allows risk stratification and prevention strategies in patients requiring long-term vascular access.

6. MRCP relevance: SVCO is a common MRCP Part 2 written and PACES scenario, testing differential diagnosis, investigation strategy, and understanding of oncological emergencies.

---

Visual Summary

Visual assets to be added:

• Anatomical diagram: SVC anatomy, azygos system, and collateral venous pathways
• Clinical photograph: Facial plethora, periorbital oedema, and dilated chest wall veins
• CT venogram: Axial and coronal images showing SVC compression by mediastinal mass
• Chest radiograph: Widened mediastinum and right hilar mass in lung cancer
• Management algorithm: SVCO assessment and treatment pathway
• Pemberton sign demonstration: Technique and positive finding
• Stenting procedure: Fluoroscopic images of SVC stent placement

---

Epidemiology

Incidence and Prevalence

• Annual incidence: Approximately 15,000 cases per year in the United States [1]
• Lung cancer association: SVCO occurs in 2-4% of all lung cancer patients, and 10-15% of small cell lung cancer patients [2,18]
• Lymphoma association: SVCO develops in 2-4% of non-Hodgkin lymphoma patients, 8-12% of mediastinal lymphomas [3]
• Iatrogenic causes: Device-related SVCO incidence is increasing, estimated at 0.3-1% per year in patients with long-term central venous catheters [14]

Demographics

Causes of SVCO

Risk Factors

Malignant SVCO:

• Cigarette smoking (lung cancer)
• Right upper lobe or right hilar lung tumours (anatomical proximity to SVC)
• Mediastinal lymphadenopathy
• History of malignancy

Thrombotic SVCO:

• Central venous catheterisation (especially long-term, e.g., haemodialysis, chemotherapy)
• Transvenous pacemaker or defibrillator leads
• Hypercoagulable states (malignancy, thrombophilia)
• Previous thoracic radiotherapy (radiation-induced fibrosis and stenosis) [15]

---

Aetiology & Pathophysiology

Anatomy of the Superior Vena Cava

The SVC is a thin-walled, low-pressure vessel approximately 6-8 cm in length and 1.5-2 cm in diameter, formed by the confluence of the left and right brachiocephalic veins at the level of the first rib. [1] It descends through the right superior mediastinum, closely related to:

• Anteriorly: Thymus (or remnant), anterior mediastinal lymph nodes
• Posteriorly: Right main bronchus, trachea
• Laterally: Right lung and pleura, right phrenic nerve
• Medially: Ascending aorta, pretracheal and paratracheal lymph nodes

The SVC enters the right atrium at the level of the third costal cartilage. Its thin wall and low intravascular pressure make it vulnerable to external compression by mediastinal masses or direct tumour invasion. [4]

Venous Drainage and Collateral Circulation

The SVC drains blood from:

• Head and neck (via internal jugular veins)
• Upper extremities (via subclavian veins)
• Upper thorax and chest wall

Collateral venous pathways develop when SVC flow is obstructed, including: [4,20]

Key principle: Gradual obstruction (e.g., slow-growing thymoma) allows extensive collateral development, resulting in mild symptoms. Rapid obstruction (e.g., aggressive SCLC, acute thrombosis) causes severe symptoms due to inadequate collateral formation. [4]

Mechanisms of SVCO

1. Extrinsic Compression (most common):

• Mediastinal tumour compressing SVC externally
• Right lung malignancies (anatomical proximity)
• Enlarged mediastinal lymph nodes (lymphoma, metastatic disease)
• Mechanism: Thin SVC wall is easily compressed by adjacent masses [2]

2. Direct Tumour Invasion:

• Malignant cells invade SVC wall
• Causes intraluminal narrowing and thrombosis
• Common in aggressive lung cancers [2]

3. Intraluminal Thrombosis:

• Central venous catheter-induced endothelial injury and stasis [14]
• Hypercoagulable state (malignancy-associated)
• Pacemaker/ICD lead thrombosis [15]
• May occur on background of external compression

4. Fibrotic Stricture:

• Post-radiation fibrosis and stenosis
• Fibrosing mediastinitis (granulomatous infections: histoplasmosis, TB)
• Chronic indwelling device irritation [19]

Pathophysiology of Symptoms

Venous hypertension cascade:

1. SVC obstruction → Impaired venous return from head, neck, arms
2. Increased venous pressure → Elevated hydrostatic pressure in capillaries
3. Fluid extravasation → Interstitial oedema (face, neck, arms)
4. Collateral formation → Visible distended veins on chest wall and neck
5. Laryngeal oedema (if severe) → Airway narrowing → Stridor
6. Cerebral venous hypertension (if severe) → Increased ICP → Headache, confusion, papilloedema [4,5]

Time course determines severity:

• Acute onset (less than 2 weeks): Severe symptoms, minimal collaterals, higher risk of life-threatening features
• Subacute/chronic (> 2-4 weeks): Mild-moderate symptoms, extensive collaterals, better tolerated [4]

Life-Threatening Features: Pathophysiology

Laryngeal oedema and stridor: [5]

• Venous hypertension causes laryngeal mucosal oedema
• Progressive airway narrowing
• Stridor indicates critical airway compromise
• Risk of complete airway obstruction
• Medical emergency: Requires dexamethasone, consider intubation, urgent stenting

Cerebral oedema: [5]

• Impaired cerebral venous drainage → increased intracranial pressure
• Symptoms: Severe headache (worse on lying flat), confusion, visual disturbance, seizures
• Signs: Papilloedema, altered mental status, focal neurology (rare)
• Risk of herniation syndromes
• Medical emergency: Requires dexamethasone, head elevation, urgent stenting/treatment

Cardiovascular collapse (rare):

• Severe reduction in venous return → decreased cardiac preload → reduced cardiac output
• Presents with syncope, hypotension
• Extremely rare; usually only with very rapid, complete SVC occlusion [1]

---

Clinical Presentation

Symptoms

Cardinal symptoms (in order of frequency): [4,16]

Symptom evolution:

• Early (days-weeks): Sensation of facial/neck tightness, collar feels tight, breathlessness
• Established (weeks-months): Obvious facial oedema, visible neck veins, arm swelling, orthopnoea
• Severe/late: Stridor, confusion, inability to lie flat, severe dyspnoea

Positional exacerbation (key clinical clue):

• Symptoms worse on lying flat, bending forward, or straining
• Relieved by sitting upright or standing
• Patients often sleep propped up on multiple pillows

Signs

General inspection:

• Facial plethora: Dusky red/cyanotic facial discolouration
• Periorbital oedema: Swollen eyelids, "puffy" appearance
• Conjunctival oedema (chemosis): Swollen conjunctivae
• Facial oedema: Non-pitting, bilateral
• Neck oedema: Thickened neck, loss of normal contours

Venous findings:

• Distended neck veins: Non-pulsatile (vs. JVP in heart failure, which is pulsatile), fixed distension not varying with respiration
• Chest wall collateral veins: Dilated superficial veins over anterior chest, shoulders, upper abdomen (flow direction: downward toward IVC)
• Upper limb oedema: Swelling of one or both arms

Respiratory signs:

• Stridor: Inspiratory wheeze indicating laryngeal oedema (URGENT)
• Tachypnoea: Increased respiratory rate
• Reduced air entry: From pleural effusion or underlying lung pathology

Neurological signs (cerebral oedema):

• Confusion or altered mental status
• Papilloedema: On fundoscopy
• Seizures (rare, severe cases)

Underlying malignancy signs:

• Supraclavicular lymphadenopathy: Palpable nodes (lung cancer, lymphoma)
• Horner syndrome: Ptosis, miosis, anhidrosis (Pancoast tumour involving sympathetic chain)
• Hepatomegaly: Metastatic disease
• Cachexia: Advanced malignancy

Pemberton Sign

Technique:

1. Patient raises both arms above the head
2. Maintain position for 60 seconds
3. Observe for development of:
   • Facial plethora (flushing, redness)
   • Facial cyanosis
   • Respiratory distress
   • Venous engorgement

Interpretation:

• Positive sign: Development of plethora, cyanosis, or respiratory distress within 1 minute
• Mechanism: Arm elevation compresses residual SVC flow between clavicles and thoracic inlet, acutely worsening obstruction
• Sensitivity: 50-60% (not all SVCO patients will be positive)
• Specificity: High (> 90%) — positive sign strongly suggests SVCO or superior mediastinal mass [16]

Clinical utility: Simple bedside test; positive sign in appropriate clinical context supports SVCO diagnosis and warrants urgent imaging.

Red Flags (Immediate Action Required)

---

Clinical Examination

Systematic Examination Approach

General inspection:

1. Patient position: Sitting upright (unable to lie flat), distressed
2. Facial appearance: Plethora (red/dusky colour), oedema, periorbital swelling
3. Neck: Thickened appearance, non-pulsatile distended veins
4. Breathing: Tachypnoea, accessory muscle use, listen for stridor

Head and neck:

1. Face: Periorbital oedema, facial swelling (non-pitting)
2. Eyes: Conjunctival oedema (chemosis), proptosis (rare)
3. Fundoscopy: Papilloedema, venous engorgement
4. Neck veins: Distended, non-pulsatile, fixed (not varying with position or respiration)
5. Lymph nodes: Palpate supraclavicular, cervical, axillary nodes

Chest:

1. Inspection:
   • Dilated superficial veins over chest wall (collaterals)
   • Flow direction: Use fingertip to occlude vein, observe refill direction (cephalad vs. caudad)
   • Asymmetry, chest wall masses
2. Palpation: Tracheal deviation (mediastinal mass), apex beat
3. Percussion: Mediastinal dullness, pleural effusion
4. Auscultation: Reduced air entry, stridor (upper airway), wheeze, lung consolidation

Upper limbs:

1. Inspection: Oedema (unilateral or bilateral), dilated arm veins
2. Palpation: Pitting or non-pitting oedema, temperature (warm vs. cool), radial pulse
3. Horner syndrome: Ptosis, miosis, anhidrosis (Pancoast tumour)

Cardiovascular:

• Blood pressure (both arms)
• Heart sounds, murmurs
• Peripheral pulses

Neurological (if cerebral oedema suspected):

• GCS/mental status: Confusion, drowsiness
• Fundoscopy: Papilloedema
• Cranial nerves: Assess for focal deficits
• Tone, power, reflexes: Assess for asymmetry (rare)

Pemberton sign: Perform as described above.

Typical Examination Findings in SVCO

---

Differential Diagnosis

Key Differentials

Clinical Clues to Distinguish SVCO

Features favouring SVCO:

• Non-pulsatile neck veins (vs. pulsatile JVP in heart failure or tricuspid regurgitation)
• Facial/periorbital oedema (uncommon in most other causes)
• Chest wall collateral veins (pathognomonic)
• Pemberton sign positive
• Symptoms worse on lying flat, bending forward

Features favouring alternative diagnoses:

• Pulsatile JVP: Congestive heart failure, tricuspid regurgitation, constrictive pericarditis
• Bilateral leg oedema more than arm oedema: Heart failure, nephrotic syndrome
• Rapid onset (less than 24 hours): Angioedema
• Urticaria, pruritus: Angioedema, allergic reaction
• Unilateral arm swelling only: Axillary vein thrombosis, upper limb DVT

---

Investigations

Blood Tests

Note: Blood tests do not diagnose SVCO but help assess underlying cause and guide management.

Imaging

Chest Radiograph (CXR)

Purpose: Initial imaging; identifies mediastinal mass or lung pathology

Findings suggestive of SVCO: [6]

• Widened mediastinum (> 8 cm on PA film)
• Right hilar mass (lung cancer)
• Mediastinal mass (lymphoma, thymoma)
• Pleural effusion (right > left)
• Right upper lobe mass (proximity to SVC)
• Loss of normal mediastinal contours

Sensitivity: ~50-60% (may be normal in early or thrombotic SVCO)

Next step: CXR abnormality → Proceed to CT chest with contrast

CT Chest with Contrast (CT Venography)

Gold standard investigation for SVCO [6]

Protocol:

• IV contrast administration (venous phase imaging critical)
• Axial, coronal, and sagittal reconstructions
• Imaging of neck to upper abdomen (assess extent)

Findings:

• Site of obstruction: Identifies level and extent of SVC narrowing/occlusion
• Cause: Extrinsic compression (mass), direct invasion, intraluminal thrombus
• Collateral veins: Maps azygos, internal mammary, and other collateral pathways
• Underlying pathology: Lung mass, mediastinal lymphadenopathy, thymoma
• Pleural effusion, pericardial effusion
• Metastatic disease: Mediastinal, liver, adrenal, bone

Sensitivity and specificity: > 95% for diagnosing SVCO [6]

Contraindications:

• Renal impairment (contrast nephropathy risk)
• Contrast allergy (use alternative or pre-medicate)

Alternatives if contrast contraindicated:

• MRI venography
• Doppler ultrasound (limited for SVC but can assess arm veins)

MRI Venography

Indications:

• Contrast allergy or renal impairment
• Further characterisation of mediastinal mass
• Assessment of vascular invasion

Advantages: No ionising radiation, multiplanar imaging, excellent soft tissue contrast

Disadvantages: Longer acquisition time, less available, poorer spatial resolution than CT

Tissue Diagnosis

Critical principle: Obtain histological diagnosis before starting chemotherapy or radiotherapy (unless life-threatening features present). [7]

Why tissue diagnosis is essential:

1. Guides treatment: Chemotherapy (SCLC, lymphoma) vs. radiotherapy (NSCLC) vs. surgery (thymoma)
2. Avoids inappropriate treatment
3. Allows prognostication and treatment planning

Biopsy Methods

First-line approach:

• Palpable lymph node (supraclavicular, cervical, axillary) → Excision biopsy (simplest, best tissue for diagnosis)
• No palpable nodes + lung mass → Bronchoscopy or CT-guided biopsy
• Mediastinal lymphadenopathy → EBUS-TBNA (less invasive than mediastinoscopy)
• Pleural effusion → Pleural fluid sampling (cytology, flow cytometry if lymphoma suspected)

When to treat without tissue diagnosis: [5,7]

• Stridor with impending airway obstruction
• Cerebral oedema with reduced GCS
• Life-threatening cardiorespiratory compromise
• Action: Emergency dexamethasone, stenting, then biopsy once stabilised (or treat empirically if unstable)

---

Classification & Staging

Classification by Aetiology

Malignant SVCO (85-90% of cases):

• Lung cancer (SCLC, NSCLC)
• Lymphoma (Hodgkin, non-Hodgkin)
• Metastatic disease (breast, colorectal, germ cell)
• Thymoma, thymic carcinoma

Benign SVCO (10-15% of cases):

• Thrombosis (catheter-related, pacemaker leads)
• Fibrosing mediastinitis (histoplasmosis, tuberculosis, idiopathic)
• Retrosternal goitre
• Aortic aneurysm

Classification by Mechanism

1. Extrinsic compression: Mass compressing SVC externally
2. Direct invasion: Tumour invading SVC wall
3. Intraluminal thrombosis: Thrombus within SVC lumen
4. Fibrotic stricture: Scar tissue narrowing SVC

Severity Grading (Clinical)

---

Management

Immediate Management (If Life-Threatening Features Present)

Indications for emergency intervention: [5]

• Stridor (laryngeal oedema)
• Confusion, reduced GCS, papilloedema (cerebral oedema)
• Severe respiratory distress
• Syncope (reduced cardiac output)

Note: Do not delay emergency treatment to obtain tissue diagnosis. Stabilise first, then pursue biopsy once patient stable. [7]

General Management (Non-Emergency Cases)

Step 1: Confirm Diagnosis

• CT chest with contrast (if not already done)
• Document SVC obstruction site, extent, cause, collaterals

Step 2: Obtain Tissue Diagnosis

• Before starting chemotherapy or radiotherapy [7]
• Use safest, highest-yield method (see Investigations section)
• Multidisciplinary discussion: Respiratory, oncology, radiology

Step 3: Supportive Measures

Step 4: Definitive Treatment (Based on Cause)

SVC Stenting (Endovascular Intervention)

First-line palliative intervention for symptomatic SVCO [8,9]

Indications:

• Symptomatic SVCO (dyspnoea, facial swelling, orthopnoea)
• Particularly if:
  • Non-chemo-sensitive tumour (NSCLC)
  • Slow response expected from chemotherapy/radiotherapy
  • Recurrent SVCO after prior treatment
  • Life-threatening features requiring rapid relief

Procedure:

• Performed by interventional radiology
• Percutaneous access (femoral vein or jugular vein)
• Fluoroscopic guidance to deploy self-expanding metallic stent across SVC stenosis
• Usually day-case or overnight stay

Outcomes: [8,9,17]

• Technical success: > 95%
• Clinical improvement: 85-95% of patients (within 24-72 hours)
• Symptom relief: Rapid (hours to days)
• Patency: Median 6-9 months (depends on underlying disease and prognosis)

Complications:

• Stent migration: 2-5%
• Stent thrombosis: 5-10% (reduced with anticoagulation)
• Bleeding: less than 2%
• Pulmonary embolism: Rare
• SVC perforation: Very rare (less than 1%)

Post-procedure:

• Anticoagulation (LMWH or DOAC) to maintain stent patency [8]
• Proceed with definitive oncological treatment

Chemotherapy

Indications: Chemo-sensitive tumours [10]

• Small cell lung cancer (SCLC): Highly chemo-sensitive; rapid tumour shrinkage often relieves SVCO without stenting
• Lymphoma: Hodgkin and non-Hodgkin lymphoma; dramatic response to chemotherapy
• Germ cell tumours: Testicular cancer with mediastinal metastases

Typical regimens:

• SCLC: Platinum-based chemotherapy (cisplatin/carboplatin + etoposide)
• Lymphoma: ABVD (Hodgkin), R-CHOP (B-cell NHL), dose-adjusted EPOCH (mediastinal large B-cell)
• Germ cell: BEP (bleomycin, etoposide, cisplatin)

Timeline:

• Symptom improvement typically within 7-14 days
• Faster than radiotherapy
• May avoid need for stenting if rapid response

Approach:

• Obtain tissue diagnosis first (unless emergency)
• Start chemotherapy promptly
• Consider stenting if severe symptoms or slow response

Radiotherapy

Indications: [11]

• Non-small cell lung cancer (NSCLC): Less chemo-sensitive; radiotherapy provides local control
• Thymoma/thymic carcinoma: Radiotherapy adjunct to surgery or primary treatment
• Palliative radiotherapy: Symptom control in advanced malignancy
• Recurrent SVCO: After failed chemotherapy

Typical regimen:

• Palliative: 20 Gy in 5 fractions or 30 Gy in 10 fractions
• Radical: 60-66 Gy in 30-33 fractions (if curative intent)

Timeline:

• Symptom improvement typically 2-4 weeks (slower than chemotherapy or stenting)

Outcomes:

• 70-80% response rate (symptom relief)
• Median symptom relief duration: 3-6 months

Limitations:

• Slower onset than stenting
• Cannot re-irradiate if recurrence (exceeds tissue tolerance)

Anticoagulation

Indications: Thrombotic SVCO [14,15]

• Central venous catheter-related thrombosis
• Pacemaker/ICD lead thrombosis
• Any SVC thrombus visible on CT

Agents:

• LMWH (e.g., enoxaparin 1.5 mg/kg once daily, or dalteparin 200 units/kg once daily)
• DOACs (e.g., apixaban 10 mg BD for 7 days, then 5 mg BD; rivaroxaban 15 mg BD for 21 days, then 20 mg once daily)
• Warfarin (target INR 2-3; less commonly used due to monitoring requirements)

Duration:

• Provoked (catheter-related): 3-6 months (or until catheter removed)
• Unprovoked or malignancy-associated: Long-term (indefinite if catheter remains, or while malignancy active)

Catheter management:

• Remove catheter if no longer needed and alternative access available
• If catheter essential (e.g., chemotherapy, haemodialysis), can attempt to preserve with anticoagulation

Surgery

Indications (rare in SVCO):

• Retrosternal goitre: Surgical excision
• Thymoma: Surgical resection (if resectable, no SVCO emergency)
• SVC reconstruction: Rarely performed; for benign strictures (fibrosing mediastinitis) not responding to stenting

---

Management Algorithm

SVCO Suspected (facial swelling, dilated veins, dyspnoea)
    ↓
CT Chest with Contrast (confirm SVCO, identify cause)
    ↓
Life-threatening features? (Stridor, cerebral oedema, severe distress)
    ↓
YES → EMERGENCY MANAGEMENT
    - Sit upright, oxygen
    - Dexamethasone 16 mg IV
    - Urgent interventional radiology (SVC stenting)
    - Airway assessment (ENT/anaesthetics)
    - Stabilise, then obtain tissue diagnosis
    ↓
NO → Obtain Tissue Diagnosis
    - Bronchoscopy, CT biopsy, EBUS, lymph node biopsy
    - Histology + staging
    ↓
Definitive Treatment Based on Cause:
    ↓
SMALL CELL LUNG CANCER / LYMPHOMA (chemo-sensitive)
    - Start chemotherapy (platinum-based for SCLC, ABVD/R-CHOP for lymphoma)
    - Dexamethasone 8 mg BD
    - Stenting if severe symptoms or slow response
    ↓
NON-SMALL CELL LUNG CANCER (less chemo-sensitive)
    - SVC stenting (first-line for symptom relief)
    - Radiotherapy ± chemotherapy (stage-dependent)
    - Anticoagulation post-stenting
    ↓
THROMBOTIC SVCO (catheter-related)
    - Anticoagulation (LMWH or DOAC)
    - Remove catheter if possible
    - Stenting if persistent symptoms despite anticoagulation
    ↓
BENIGN STRICTURE (fibrosing mediastinitis)
    - SVC stenting
    - Treat underlying cause (antifungals for histoplasmosis)
    ↓
Follow-up and Monitoring
    - Oncology follow-up
    - Symptom reassessment
    - Repeat imaging if recurrence suspected

---

Complications

Complications of SVCO Itself

Complications of SVC Stenting

Complications of Treatment (Chemotherapy/Radiotherapy)

• Chemotherapy: Myelosuppression, neutropenic sepsis, nausea, alopecia (regimen-dependent)
• Radiotherapy: Oesophagitis, pneumonitis, skin erythema, fatigue
• Late radiation effects: Fibrosis, radiation-induced stricture (can worsen SVCO)

---

Prognosis & Outcomes

Symptom Relief

Overall Prognosis (Depends on Underlying Cause)

Key principle: SVCO itself is rarely fatal; prognosis determined by underlying malignancy. [13]

Prognostic Factors

Poor prognosis:

• NSCLC (vs. SCLC or lymphoma)
• Advanced stage at presentation
• Poor performance status (ECOG 3-4)
• Cerebral or laryngeal oedema at presentation
• Failure to respond to initial treatment

Favourable prognosis:

• Chemo-sensitive tumours (SCLC, lymphoma, germ cell)
• Limited-stage disease
• Good performance status (ECOG 0-1)
• Rapid response to treatment
• Benign causes (thrombotic SVCO)

---

Special Scenarios

SCLC-Related SVCO

Clinical features:

• Rapid onset (weeks)
• Often extensive-stage disease
• High tumour burden, mediastinal lymphadenopathy
• Paraneoplastic syndromes (SIADH, Cushing syndrome, Lambert-Eaton syndrome) may coexist

Management approach:

• Tissue diagnosis: Bronchoscopy, CT biopsy, or pleural fluid cytology
• First-line treatment: Platinum-based chemotherapy (cisplatin/carboplatin + etoposide)
• Stenting: Reserve for severe symptoms or slow response (most improve with chemotherapy alone) [10]
• Prognosis: Median survival 6-12 months; better than NSCLC

NSCLC-Related SVCO

Clinical features:

• Slower onset (weeks to months)
• Right upper lobe or right hilar tumours most common
• May have extensive mediastinal invasion

Management approach:

• Tissue diagnosis: Essential for histology and molecular profiling (EGFR, ALK, PD-L1)
• First-line treatment: SVC stenting for rapid symptom relief [11]
• Subsequent treatment:
  • Targeted therapy if EGFR/ALK mutation (erlotinib, osimertinib, alectinib)
  • Immunotherapy if PD-L1 positive (pembrolizumab, nivolumab)
  • Radiotherapy for local control
• Prognosis: Median survival 3-6 months; poorer than SCLC

Lymphoma-Related SVCO

Clinical features:

• More common in young adults (mediastinal large B-cell lymphoma)
• B-symptoms (fever, night sweats, weight loss) often present
• Bulky mediastinal mass

Management approach:

• Tissue diagnosis: Lymph node biopsy (excision preferred for architecture assessment), EBUS-TBNA, mediastinoscopy
• First-line treatment: Chemotherapy (ABVD for Hodgkin, R-CHOP or dose-adjusted EPOCH for NHL)
• Stenting: Rarely needed (rapid response to chemotherapy expected) [10]
• Prognosis: Good (24-36 months median survival); potentially curable

Catheter-Related Thrombotic SVCO

Clinical features:

• History of long-term central venous catheter (chemotherapy, haemodialysis, parenteral nutrition)
• Unilateral arm swelling initially, then neck/facial swelling
• CT shows intraluminal thrombus ± catheter visible

Management approach:

• Anticoagulation: LMWH or DOAC; continue for 3-6 months or while catheter in situ [14,15]
• Catheter management: Remove if no longer needed; if essential, can attempt preservation with anticoagulation
• Stenting: If persistent symptoms despite anticoagulation
• Thrombolysis: Rarely used (risk of bleeding); consider if acute thrombosis and severe symptoms

Prevention:

• Ultrasound-guided insertion (reduce vein trauma)
• Use smallest gauge catheter feasible
• Consider prophylactic anticoagulation in high-risk patients (cancer, thrombophilia)

Fibrosing Mediastinitis

Causes:

• Histoplasmosis (endemic areas: Ohio/Mississippi River valleys, USA)
• Tuberculosis (endemic areas)
• Idiopathic (autoimmune, IgG4-related disease)

Clinical features:

• Gradual onset (months to years)
• Extensive collateral circulation
• Mild to moderate symptoms

Management approach:

• Treat underlying cause: Antifungals (itraconazole for histoplasmosis), antituberculous therapy (if active TB), corticosteroids (if IgG4-related)
• SVC stenting: For symptomatic relief; often good long-term patency
• Surgery: SVC reconstruction rarely required (complex, high-risk)

---

MRCP Exam Focus

High-Yield Facts for Written Exam (Part 1 and Part 2)

1. Most common cause of SVCO: Lung cancer (50-70%), with SCLC more common than NSCLC. [2]
2. Second most common cause: Lymphoma (10-15%), particularly mediastinal large B-cell lymphoma. [3]
3. Increasing cause: Catheter-related thrombosis (10-20% of cases). [14,15]
4. Classic triad: Facial/neck swelling + dilated neck veins + upper limb oedema
5. Pemberton sign: Facial plethora and respiratory distress on raising arms above head (50-60% sensitive, > 90% specific). [16]
6. Life-threatening features: Stridor (laryngeal oedema) and cerebral oedema (confusion, papilloedema) — both require emergency intervention. [5]
7. Gold standard investigation: CT chest with IV contrast (CT venography) — sensitivity > 95%. [6]
8. Key differentiating feature from heart failure: Non-pulsatile neck veins (vs. pulsatile JVP in heart failure)
9. First-line symptomatic intervention: SVC stenting — 85-95% clinical improvement within 24-72 hours. [8,9]
10. Definitive treatment: Depends on cause — chemotherapy for SCLC/lymphoma, radiotherapy for NSCLC, anticoagulation for thrombotic SVCO. [10,11]
11. Role of dexamethasone: Reduces peritumoral and laryngeal oedema; dose 8-16 mg daily. [12]
12. Tissue diagnosis: Essential before chemotherapy/radiotherapy (unless life-threatening emergency). [7]
13. Prognosis: Determined by underlying malignancy, not SVCO itself. [13]

Common Viva Questions

Q1: "What is superior vena cava obstruction, and what are the main causes?"

Model answer: "Superior vena cava obstruction is compression, invasion, or thrombosis of the SVC, which impairs venous return from the head, neck, and upper extremities to the right atrium. The main causes are:

• Malignancy (85-90%): Lung cancer is most common (50-70%), particularly small cell and right-sided tumours. Lymphoma accounts for 10-15%, especially mediastinal large B-cell lymphoma.
• Benign causes (10-15%): Catheter-related thrombosis is increasing due to widespread use of central lines; fibrosing mediastinitis from histoplasmosis or tuberculosis; retrosternal goitre. The thin-walled SVC is vulnerable to external compression by mediastinal masses due to its low intravascular pressure." [1,2,3]

Q2: "How would you recognise SVCO clinically?"

Model answer: "SVCO presents with a characteristic clinical picture:

• Symptoms: Facial and neck swelling (worse on lying flat or bending forward), dyspnoea, arm swelling, headache (worse in morning), cough.
• Signs: Facial plethora and periorbital oedema, non-pulsatile distended neck veins (differentiating from JVP in heart failure), dilated chest wall collateral veins (flowing downward toward IVC), upper limb oedema.
• Pemberton sign: Raising both arms above the head for 1 minute induces facial plethora, cyanosis, and respiratory distress — this is highly specific for SVCO. Red flags include stridor (laryngeal oedema) and cerebral oedema (confusion, papilloedema), which indicate life-threatening complications requiring emergency intervention." [4,5,16]

Q3: "What investigations would you perform, and what is the gold standard?"

Model answer: "My investigation approach would be:

• Initial imaging: Chest radiograph may show mediastinal widening, hilar mass, or pleural effusion, but has only 50-60% sensitivity.
• Gold standard: CT chest with IV contrast (CT venography) — this confirms the diagnosis (> 95% sensitivity), identifies the site and extent of SVC obstruction, visualises the underlying cause (mass, thrombus), and maps collateral circulation.
• Tissue diagnosis: Essential before starting chemotherapy or radiotherapy. Options include bronchoscopy with endobronchial biopsy, CT-guided biopsy of the mediastinal mass, EBUS-TBNA for lymph nodes, or excision biopsy of palpable supraclavicular nodes. Lymph node excision is preferred for suspected lymphoma to assess architecture.
• Bloods: FBC, U&E, LFTs, LDH (elevated in lymphoma), tumour markers (AFP, β-hCG if germ cell tumour suspected). Tissue diagnosis can be deferred only if life-threatening features (stridor, cerebral oedema) necessitate emergency treatment." [6,7]

Q4: "How would you manage a patient with SVCO?"

Model answer: "Management depends on whether life-threatening features are present:

Emergency management (stridor, cerebral oedema, severe distress):

• Sit patient upright, high-flow oxygen
• Dexamethasone 16 mg IV (reduces laryngeal and cerebral oedema)
• Urgent interventional radiology referral for SVC stenting
• Airway assessment by ENT/anaesthetics (intubation if worsening stridor)
• Stabilise, then obtain tissue diagnosis

Non-emergency management:

1. Confirm diagnosis: CT chest with contrast
2. Obtain tissue diagnosis: Bronchoscopy, CT biopsy, lymph node biopsy
3. Supportive measures: Dexamethasone 8 mg BD, head elevation, avoid arm venepuncture
4. Definitive treatment (cause-dependent):
   • SCLC or lymphoma (chemo-sensitive): Chemotherapy is first-line (platinum-etoposide for SCLC, ABVD/R-CHOP for lymphoma); stenting if severe symptoms or slow response
   • NSCLC (less chemo-sensitive): SVC stenting for rapid symptom relief, then radiotherapy ± chemotherapy or targeted therapy
   • Thrombotic SVCO: Anticoagulation (LMWH or DOAC), remove catheter if feasible, stenting if persistent symptoms

SVC stenting provides rapid symptom relief (85-95% improvement within 24-72 hours) and is first-line for palliative symptom control." [5,7,8,9,10,11]

Q5: "What is the prognosis, and what factors influence it?"

Model answer: "Prognosis depends on the underlying cause, not SVCO itself:

• SCLC: Median survival 6-12 months; better than NSCLC due to chemo-sensitivity
• NSCLC: Median survival 3-6 months; poorer prognosis
• Lymphoma: 24-36 months with treatment; potentially curable
• Benign causes (thrombotic, fibrosing mediastinitis): Normal life expectancy if treated appropriately

Favourable prognostic factors include chemo-sensitive tumours, limited-stage disease, good performance status, and rapid response to treatment. Poor prognosis is associated with NSCLC, advanced stage, poor performance status, and life-threatening features (cerebral or laryngeal oedema) at presentation." [13]

Common Mistakes to Avoid

❌ "SVCO is always a medical emergency requiring immediate radiotherapy"

• Correction: Most SVCO cases are NOT immediately life-threatening. Only stridor and cerebral oedema constitute true emergencies. Tissue diagnosis should be obtained before starting treatment in stable patients. [7]

❌ "JVP is raised in SVCO"

• Correction: SVCO causes distended neck veins, but they are non-pulsatile (not true JVP). JVP is pulsatile and seen in congestive heart failure, tricuspid regurgitation, or constrictive pericarditis.

❌ "All SVCO patients need SVC stenting"

• Correction: Chemo-sensitive tumours (SCLC, lymphoma) often respond rapidly to chemotherapy alone without need for stenting. Stenting is reserved for severe symptoms or slow response. [10]

❌ "Chest X-ray is sufficient to diagnose SVCO"

• Correction: CXR has only 50-60% sensitivity. CT chest with contrast is the gold standard (> 95% sensitivity). [6]

❌ "You should never obtain tissue diagnosis in SVCO"

• Correction: Tissue diagnosis is essential to guide treatment (chemotherapy vs. radiotherapy vs. anticoagulation). Only defer if life-threatening features require immediate intervention. [7]

PACES Scenarios

Scenario 1: History-taking station

• Patient presenting with facial swelling, dyspnoea, headache
• Elicit red flags (stridor, confusion), smoking history, weight loss, night sweats
• Explain need for urgent imaging and possible tissue biopsy

Scenario 2: Communication station

• Explain SVCO diagnosis to patient with newly diagnosed lung cancer
• Discuss need for biopsy, treatment options (chemotherapy, stenting, radiotherapy)
• Address concerns about prognosis and quality of life

Scenario 3: Data interpretation

• CT chest report showing SVC obstruction due to right hilar mass
• Interpret findings, discuss differential diagnosis (SCLC vs. NSCLC vs. lymphoma)
• Outline investigation plan (bronchoscopy, tissue diagnosis) and management

---

Patient & Family Explanation

What is Superior Vena Cava Obstruction?

Superior vena cava obstruction (SVCO) is a condition where a large vein in your chest called the superior vena cava becomes blocked or narrowed. This vein normally carries blood from your head, neck, and arms back to your heart. When it's blocked, blood builds up in these areas, causing swelling and other symptoms.

What causes SVCO?

The most common cause is a tumour in the chest pressing on or invading the vein. This is often due to:

• Lung cancer (the most common cause)
• Lymphoma (a cancer of the lymphatic system)
• Other cancers that have spread to the chest

Less commonly, SVCO can be caused by:

• A blood clot in the vein (sometimes related to a long-term intravenous line or pacemaker wire)
• Scar tissue in the chest from previous infections or radiation treatment
• An enlarged thyroid gland pressing on the vein

What are the symptoms?

Common symptoms include:

• Swelling of the face and neck (especially when lying down or bending forward)
• Swelling of one or both arms
• Shortness of breath (difficulty breathing, especially when lying flat)
• Visible veins on the chest and neck
• Headache (often worse in the morning)
• Cough
• Difficulty swallowing

Warning signs that need urgent medical attention:

• Noisy breathing (stridor) or difficulty breathing
• Confusion or feeling very drowsy
• Worsening headache or vision problems

If you experience these, seek emergency medical help immediately.

How is SVCO diagnosed?

Your doctor will:

1. Ask about your symptoms and examine you (checking for facial swelling, swollen veins, and arm swelling)
2. Order a CT scan of your chest with dye (contrast) — this is the best test to confirm SVCO and see what's causing it
3. Obtain a tissue sample (biopsy) — a small piece of the tumour or lymph node is taken to identify the exact cause under a microscope. This helps guide the right treatment.

How is SVCO treated?

Treatment depends on the cause:

1. If caused by cancer:

• Chemotherapy: If you have a cancer that responds well to chemotherapy (such as small cell lung cancer or lymphoma), this may be the first treatment. It shrinks the tumour and relieves the blockage.
• Stent placement: A small metal tube (stent) can be placed inside the vein to hold it open. This is done by a specialist doctor (interventional radiologist) and provides quick relief within 1-2 days. It's often used for symptom relief while other treatments work.
• Radiotherapy: High-energy X-rays target the tumour to shrink it and relieve the blockage. This takes a few weeks to work.

2. If caused by a blood clot:

• Blood-thinning medication (anticoagulation): This prevents the clot from growing and allows your body to gradually dissolve it.
• If the clot is related to a central line or pacemaker, your doctor will discuss whether the device can be removed.

3. Supportive treatments:

• Steroids (dexamethasone): Reduces swelling and inflammation around the blockage
• Sitting upright: Sleeping propped up on pillows helps reduce swelling and breathlessness
• Oxygen: If you're short of breath

What is the outlook?

The outlook depends mainly on the underlying cause:

• If SVCO is caused by a cancer that responds well to chemotherapy (like small cell lung cancer or lymphoma), symptoms often improve quickly with treatment.
• If caused by a blood clot, treatment with blood thinners and stent placement (if needed) can lead to good symptom control.
• For cancers that are harder to treat (like non-small cell lung cancer), stenting can provide good symptom relief to improve quality of life.

Your medical team will discuss your individual situation, treatment options, and likely outcomes with you.

Where can I find more information and support?

• Macmillan Cancer Support: www.macmillan.org.uk | Helpline: 0808 808 00 00
• Cancer Research UK: www.cancerresearchuk.org | Nurse helpline: 0808 800 4040
• British Lung Foundation: www.blf.org.uk | Helpline: 03000 030 555
• Lymphoma Action: www.lymphoma-action.org.uk | Helpline: 0808 808 5555
• Thrombosis UK (for blood clot information): www.thrombosisuk.org

---

References

1. Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med. 2007;356(18):1862-1869. doi:10.1056/NEJMcp067190 PMID: 17476012

2. Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine (Baltimore). 2006;85(1):37-42. doi:10.1097/01.md.0000198474.99876.f0 PMID: 16523051

3. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clin Oncol (R Coll Radiol). 2002;14(5):338-351. doi:10.1053/clon.2002.0095 PMID: 12555869

4. Yellin A, Rosen A, Reichert N, Lieberman Y. Superior vena cava syndrome. The myth—the facts. Am Rev Respir Dis. 1990;141(5 Pt 1):1114-1118. doi:10.1164/ajrccm/141.5_Pt_1.1114 PMID: 2187382

5. Wan JF, Bezjak A. Superior vena cava syndrome. Emerg Med Clin North Am. 2009;27(2):243-255. doi:10.1016/j.emc.2009.01.003 PMID: 19447308

6. Trigaux JP, Coche E, Reynders P, Schoenaers J. CT imaging of superior vena cava obstruction. J Thorac Imaging. 1999;14(2):145-152. doi:10.1097/00005382-199904000-00014 PMID: 10210490

7. Straka C, Ying J, Kong FM, et al. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome. Springerplus. 2016;5:229. doi:10.1186/s40064-016-1900-7 PMID: 27006868

8. Uberoi R. Quality assurance guidelines for superior vena cava stenting in malignant disease. Cardiovasc Intervent Radiol. 2006;29(3):319-322. doi:10.1007/s00270-005-0284-9 PMID: 16502168

9. Kalra M, Gloviczki P, Andrews JC, et al. Open surgical and endovascular treatment of superior vena cava syndrome caused by nonmalignant disease. J Vasc Surg. 2003;38(2):215-223. doi:10.1016/s0741-5214(03)00333-1 PMID: 12891099

10. Perez-Soler R, McLaughlin P, Velasquez WS, et al. Clinical features and results of management of superior vena cava syndrome secondary to lymphoma. J Clin Oncol. 1984;2(4):260-266. doi:10.1200/JCO.1984.2.4.260 PMID: 6371047

11. Armstrong BA, Perez CA, Simpson JR, Hederman MA. Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys. 1987;13(4):531-539. doi:10.1016/0360-3016(87)90067-9 PMID: 3558043

12. Rodrigues CI, Njo KH, Karim AB. Hypofractionated radiation therapy in the treatment of superior vena cava syndrome. Lung Cancer. 1993;10(3-4):221-228. doi:10.1016/0169-5002(93)90362-7 PMID: 8305653

13. Schraufnagel DE, Hill R, Leech JA, Pare JA. Superior vena caval obstruction. Is it a medical emergency? Am J Med. 1981;70(6):1169-1174. doi:10.1016/0002-9343(81)90818-7 PMID: 7234890

14. Kee ST, Kinoshita L, Razavi MK, et al. Superior vena cava syndrome: treatment with catheter-directed thrombolysis and endovascular stent placement. Radiology. 1998;206(1):187-193. doi:10.1148/radiology.206.1.9423671 PMID: 9423671

15. Otten TR, Stein PD, Patel KC, et al. Thromboembolic disease involving the superior vena cava and brachiocephalic veins. Chest. 2003;123(3):809-812. doi:10.1378/chest.123.3.809 PMID: 12628882

16. Wallace S, Brong-Jeng G, Jackson D, et al. Obstruction of the superior vena cava: a review of 60 cases. AJR Am J Roentgenol. 1975;123(2):316-328. doi:10.2214/ajr.123.2.316 PMID: 1119569

17. Nicholson AA, Ettles DF, Arnold A, et al. Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol. 1997;8(5):781-788. doi:10.1016/s1051-0443(97)70658-7 PMID: 9314371

18. Scagliotti GV, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(11):1835-1842. doi:10.1200/JCO.2009.26.1321 PMID: 20212250

19. Loyd JE, Tillman BF, Atkinson JB, Des Prez RM. Mediastinal fibrosis complicating histoplasmosis. Medicine (Baltimore). 1988;67(5):295-310. PMID: 3045575

20. Qanadli SD, El Hajjam M, Mignon F, et al. Subacute and chronic benign superior vena cava obstructions: endovascular treatment with self-expanding metallic stents. AJR Am J Roentgenol. 1999;173(1):159-164. doi:10.2214/ajr.173.1.10397118 PMID: 10397118

---